Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFENCE study of denosumab versus placebo in high-risk smoldering multiple myeloma and early SLiM-CRAB myeloma
MOH_2020-06-23_009064Phase 2Not yet recruiting
- Sponsor
- AGMT
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in multiple myeloma (MM) and smoldering multiple myeloma (SMM) comparing Denosumab study drug arm with Placebo arm (2 arms). Planned start Feb 2020; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on MOH_2020-06-23_009064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-23_009064.